CancerDrs

Ovarian Cancer clinical trials in New Jersey

42 actively recruiting ovarian cancer trials at 43 sites across New Jersey.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in New Jersey:
  • Cooper Hospital University Medical Center — Camden, New Jersey
  • Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
  • Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus — Elizabeth, New Jersey
  • Englewood Hospital and Medical Center — Englewood, New Jersey
  • Hackensack University Medical Center — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…

Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
  • Summit Medical Group — Berkeley Heights, New Jersey
  • Cooper Hospital University Medical Center — Camden, New Jersey
  • Summit Health - Florham Park Campus — Florham Park, New Jersey
  • The Cancer Institute of New Jersey Hamilton — Hamilton, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in New Jersey:
  • Hackensack University Medical Center — Hackensack, New Jersey
  • Morristown Medical Center — Morristown, New Jersey
  • Jersey Shore Medical Center — Neptune City, New Jersey
  • Saint Peter's University Hospital — New Brunswick, New Jersey
  • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…

Sponsor: GOG Foundation
NCT ID: NCT05659381
Sites in New Jersey:
  • Holy Name Medical Center — Teaneck, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary perito…

Sponsor: AstraZeneca
NCT ID: NCT07218809
Sites in New Jersey:
  • Research Site — Camden, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Sites in New Jersey:
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0081) — Hackensack, New Jersey
  • Rutgers Cancer Institute of New Jersey ( Site 0071) — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

A Study of Intra-operative Imaging in Women With Ovarian Cancer

The purpose of this study is to find out whether using the PINPOINT imaging system intra-operatively can reduce the risk of anastomotic leaks and other complications after surgery for ovarian cancer, compared with standard intra-operative …

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT04878094
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in New Jersey:
  • Hunterdon Medical Center — Flemington, New Jersey
  • Monmouth Medical Center Southern Campus — Lakewood, New Jersey
  • Saint Barnabas Medical Center — Livingston, New Jersey
  • Monmouth Medical Center — Long Branch, New Jersey
  • Memorial Sloan Kettering Monmouth — Middletown, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with fo…

Sponsor: AbbVie
NCT ID: NCT06890338
Sites in New Jersey:
  • Rutgers Cancer Institute of New Jersey /ID# 274358 — New Brunswick, New Jersey
  • Holy Name Medical Center /ID# 276240 — Teaneck, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in New Jersey:
  • MD Anderson Cancer Center at Cooper- Two Cooper Plaza — Camden, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine …

Sponsor: AbbVie
NCT ID: NCT07059845
Sites in New Jersey:
  • Md Anderson Cancer Center At Cooper /ID# 278390 — Camden, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in New Jersey:
  • Hackensack University Medical Center — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

Sponsor: AstraZeneca
NCT ID: NCT05489211
Sites in New Jersey:
  • Research Site — East Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESA…

Sponsor: GlaxoSmithKline
NCT ID: NCT04641247
Sites in New Jersey:
  • GSK Investigational Site — Morristown, New Jersey
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in New Jersey:
  • John Theurer Cancer Center — Hackensack, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer t…

Sponsor: AbbVie
NCT ID: NCT07024784
Sites in New Jersey:
  • Holy Name Medical Center /ID# 279017 — Teaneck, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Isoquercetin in People With Ovarian Cancer

The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07303894
Sites in New Jersey:
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group. Depending on which group they are in, they will receive either acute…

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06290193
Sites in New Jersey:
  • Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (Limited protocol activities) — Montvale, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in New Jersey:
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tu…

Sponsor: Xencor, Inc.
NCT ID: NCT06276491
Sites in New Jersey:
  • The John Theruer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
View on ClinicalTrials.gov →

Showing 25 of 42 trials with sites in New Jersey. See all ovarian cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27